Market Overview

Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade

Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade

Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. generic business, and certain product divestments. Non-GAAP income fell a less-than-expected to 68 cents per share.

The Analyst

Reviewing the results, Morgan Stanley analyst David Risinger upgraded Teva from Equal-Weight to Overweight and lifted the price target from $20 to $27.

The Thesis

Teva can deliver additional cost-cutting and earnings upside in the coming years, given that it's only into the first year of its three-year restructuring plan, and the 25 percent EBITDA upside in Q3, Risinger said in note.

The analyst estimates net cost cuts of $3.1 billion in 2019, relative to the 2017 base, slightly ahead of the management's target of $3 billion. Adjusted EBITDA for 2019 is likely to be an above-consensus $5.6 billion.

Risinger expects sales of new products, including Austedo and Ajovy, to deliver upside to expectations, neutralizing the Copaxone sales erosion over time.

Austedo indicated to treat movement disorder is likely to be a $1 billion product beyond 2020, and Risinger said Ajovy approved to treat migraine is estimated to generate over $1 billion in sales in the U.S. alone. He expects Ajovy to be launched in Europe in mid-2019.

Morgan Stanley expects Teva's valuation to rise, as it delivers strong performance and drives net debt/EBITDA down from 5 times to 3 times in 2020.

Price Action

Teva shares have gained about 19 percent in the year-to-date period. At time of writing, shares traded around $22.46.

Related Links:

Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

Teva Wins FDA Approval For Generic Epinephrine

Latest Ratings for TEVA

Aug 2020BarclaysUpgradesUnderweightEqual-Weight
Aug 2020SVB LeerinkMaintainsMarket Perform
Jul 2020Goldman SachsInitiates Coverage OnNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Ajovy Copaxone David RisingerAnalyst Color Upgrades Price Target Top Stories Analyst Ratings Best of Benzinga

Latest Ratings

DMYTBenchmarkInitiates Coverage On18.0
SWXB of A SecuritiesMaintains63.0
UPSB of A SecuritiesMaintains183.0
NKEB of A SecuritiesMaintains150.0
KBHB of A SecuritiesMaintains49.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at